Open AccessRole of Esomeprazole in Early Preeclampsia: A Randomized Controlled Trial
Author(s) -
Atwa Ka,
Ibrahim Zm,
Mostafa Elshaer,
Taha Ot,
Aboelroose Aa
Publication year - 2021
Publication title -
austin journal of obstetrics and gynecology
Language(s) - English
Resource type - Journals
ISSN - 2378-1386
DOI - 10.26420/austiniobstetgynecol.2021.1189
Subject(s) - medicine , esomeprazole , gestation , randomized controlled trial , preeclampsia , gestational age , obstetrics , pregnancy , gynecology , surgery , biology , genetics
Objective: To investigate the efficacy of esomeprazole in managing early preeclampsia. Methods: This randomized controlled trial was conducted at the Obstetric/Gynecology department of Suez Canal University Hospital. We included 160 women between 26-31 years of age, with a singleton pregnancy. Eighty women received esomeprazole along with expectant treatment, whereas 80 women received expectant treatment alone. They were followed up from the date of diagnosis up to four weeks after delivery. The gestational age at termination as well as any complications during the follow-up period were documented and compared between both groups. Results: The mean age of the participants was 30.64 ± 1.62. The gestation of women in the intervention group was longer than those within the control group, with a gestational age at termination of 34.53 ± 1.21 versus 32.78 ± 1.60, respectively (P<0.001). Moreover, women in the intervention group had significantly lower incidences of fits (P= 0.005), antepartum hemorrhage (P=0.005), DIC (P=0.032), and IUFD (P<0.001). Conclusions: Esomeprazole is associated with a significant prolongation of gestation in women with early preeclampsia.